Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceralasertib +/- Durvalumab in Advanced Melanoma
NCT05061134Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of ceralasertib in melanoma (4 arms), sponsored by AstraZeneca. Primary endpoints: Objective Response Rate, Change From Baseline in CD8+ T-cells Tumour Infiltration-area in the Center Tumor Region and 3 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
ceralasertib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05061134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061134.